Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF

S. A. Im; J. S. Kim; C. Gomez-Manzano; J. Fueyo; T. J. Liu; M. S. Cho; C. M. Seong; S. N. Lee; Y. K. Hong; W. K.A. Yung

doi:10.1054/bjoc.2000.1734

Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF

S. A. Im, J. S. Kim, C. Gomez-Manzano, J. Fueyo, T. J. Liu, M. S. Cho, C. M. Seong, S. N. Lee, Y. K. Hong, W. K.A. Yung

Department of Pathology

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

Increased expression of VEGF in several types of tumours has been shown to correlate with poor prognosis. We used a replication-deficient adenoviral vector containing antisense VEGF cDNA (Ad5CMV-αVEGF) to down-regulate VEGF expression and increase the efficiency of delivery of the antisense sequence in the human breast cancer cell line MDA231-MB. Transfection of these cells with Ad5CMV-αVEGF in vitro reduced secreted levels of VEGF protein without affecting cell growth. Moreover, injection of the Ad5CMV-αVEGF vector into intramammary xenografts of these cells established in nude mice inhibited tumour growth and reduced the amount of VEGF protein and the density of microvessels in those tumours relative to tumours treated with the control vector Ad5(dl312). Our results showed that antisense VEGF ₁₆₅ cDNA was efficiently delivered in vivo via an adenoviral vector and that this treatment significantly inhibited the growth of established experimental breast tumours. The Ad5CMV-αVEGF vector may be useful in targeting the tumour vasculature in the treatment of breast cancer.

Original language	English
Pages (from-to)	1252-1257
Number of pages	6
Journal	British Journal of Cancer
Volume	84
Issue number	9
DOIs	https://doi.org/10.1054/bjoc.2000.1734
State	Published - 4 May 2001

Bibliographical note

Funding Information:
This study was supported in part by a grant from Ewha Womans University Medical College Graduates’ Alumnae Association Research Fund, Korea and by US National Institutes of Health grants CA-51148 and CA-55261. We thank Polly S Lee and Mary T Wang for helpful discussion and purification of the viruses, Louis Hau and Christine Wogan for editorial assistance.

Keywords

Adenovirus
Antiangiogenesis
Breast cancer
Gene therapy
VEGF

Access to Document

10.1054/bjoc.2000.1734

Cite this

@article{2b803ecb9b37432c828391c8345ccb2a,

title = "Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF",

abstract = "Increased expression of VEGF in several types of tumours has been shown to correlate with poor prognosis. We used a replication-deficient adenoviral vector containing antisense VEGF cDNA (Ad5CMV-αVEGF) to down-regulate VEGF expression and increase the efficiency of delivery of the antisense sequence in the human breast cancer cell line MDA231-MB. Transfection of these cells with Ad5CMV-αVEGF in vitro reduced secreted levels of VEGF protein without affecting cell growth. Moreover, injection of the Ad5CMV-αVEGF vector into intramammary xenografts of these cells established in nude mice inhibited tumour growth and reduced the amount of VEGF protein and the density of microvessels in those tumours relative to tumours treated with the control vector Ad5(dl312). Our results showed that antisense VEGF 165 cDNA was efficiently delivered in vivo via an adenoviral vector and that this treatment significantly inhibited the growth of established experimental breast tumours. The Ad5CMV-αVEGF vector may be useful in targeting the tumour vasculature in the treatment of breast cancer.",

keywords = "Adenovirus, Antiangiogenesis, Breast cancer, Gene therapy, VEGF",

author = "Im, {S. A.} and Kim, {J. S.} and C. Gomez-Manzano and J. Fueyo and Liu, {T. J.} and Cho, {M. S.} and Seong, {C. M.} and Lee, {S. N.} and Hong, {Y. K.} and Yung, {W. K.A.}",

note = "Funding Information: This study was supported in part by a grant from Ewha Womans University Medical College Graduates{\textquoteright} Alumnae Association Research Fund, Korea and by US National Institutes of Health grants CA-51148 and CA-55261. We thank Polly S Lee and Mary T Wang for helpful discussion and purification of the viruses, Louis Hau and Christine Wogan for editorial assistance.",

year = "2001",

month = may,

day = "4",

doi = "10.1054/bjoc.2000.1734",

language = "English",

volume = "84",

pages = "1252--1257",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF

AU - Im, S. A.

AU - Kim, J. S.

AU - Gomez-Manzano, C.

AU - Fueyo, J.

AU - Liu, T. J.

AU - Cho, M. S.

AU - Seong, C. M.

AU - Lee, S. N.

AU - Hong, Y. K.

AU - Yung, W. K.A.

N1 - Funding Information: This study was supported in part by a grant from Ewha Womans University Medical College Graduates’ Alumnae Association Research Fund, Korea and by US National Institutes of Health grants CA-51148 and CA-55261. We thank Polly S Lee and Mary T Wang for helpful discussion and purification of the viruses, Louis Hau and Christine Wogan for editorial assistance.

PY - 2001/5/4

Y1 - 2001/5/4

N2 - Increased expression of VEGF in several types of tumours has been shown to correlate with poor prognosis. We used a replication-deficient adenoviral vector containing antisense VEGF cDNA (Ad5CMV-αVEGF) to down-regulate VEGF expression and increase the efficiency of delivery of the antisense sequence in the human breast cancer cell line MDA231-MB. Transfection of these cells with Ad5CMV-αVEGF in vitro reduced secreted levels of VEGF protein without affecting cell growth. Moreover, injection of the Ad5CMV-αVEGF vector into intramammary xenografts of these cells established in nude mice inhibited tumour growth and reduced the amount of VEGF protein and the density of microvessels in those tumours relative to tumours treated with the control vector Ad5(dl312). Our results showed that antisense VEGF 165 cDNA was efficiently delivered in vivo via an adenoviral vector and that this treatment significantly inhibited the growth of established experimental breast tumours. The Ad5CMV-αVEGF vector may be useful in targeting the tumour vasculature in the treatment of breast cancer.

AB - Increased expression of VEGF in several types of tumours has been shown to correlate with poor prognosis. We used a replication-deficient adenoviral vector containing antisense VEGF cDNA (Ad5CMV-αVEGF) to down-regulate VEGF expression and increase the efficiency of delivery of the antisense sequence in the human breast cancer cell line MDA231-MB. Transfection of these cells with Ad5CMV-αVEGF in vitro reduced secreted levels of VEGF protein without affecting cell growth. Moreover, injection of the Ad5CMV-αVEGF vector into intramammary xenografts of these cells established in nude mice inhibited tumour growth and reduced the amount of VEGF protein and the density of microvessels in those tumours relative to tumours treated with the control vector Ad5(dl312). Our results showed that antisense VEGF 165 cDNA was efficiently delivered in vivo via an adenoviral vector and that this treatment significantly inhibited the growth of established experimental breast tumours. The Ad5CMV-αVEGF vector may be useful in targeting the tumour vasculature in the treatment of breast cancer.

KW - Adenovirus

KW - Antiangiogenesis

KW - Breast cancer

KW - Gene therapy

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=17844398957&partnerID=8YFLogxK

U2 - 10.1054/bjoc.2000.1734

DO - 10.1054/bjoc.2000.1734

M3 - Article

C2 - 11336478

AN - SCOPUS:17844398957

SN - 0007-0920

VL - 84

SP - 1252

EP - 1257

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 9

ER -

Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this